Latanoprost
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Latanoprost: From Glaucoma (Ophthalmic) to Primary Hereditary Glaucoma
One-Sentence Summary
Latanoprost is a prostaglandin analogue eye drop, though its original UK-licensed indication details are not present in this Evidence Pack. The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma, with 1 clinical trial and 0 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in Evidence Pack (no licences on record) |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L2 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is marked as a data gap in the source pack. Based on the mechanistic notes accompanying this prediction, Latanoprost is a PGF2α prostaglandin analogue that activates the FP receptor, increasing uveoscleral outflow of aqueous humour and thereby lowering intraocular pressure (IOP). This is the well-established, standard mechanism of the prostaglandin analogue class in open-angle glaucoma and ocular hypertension.
Primary hereditary glaucoma shares elevated IOP as a common underlying pathology, regardless of its genetic aetiology. Since the drug’s core pharmacological action directly targets IOP reduction via aqueous humour dynamics, extending its use to hereditary forms of glaucoma is not a novel mechanistic hypothesis but a direct, biologically plausible extension of its established action — supported by a completed Phase 2 paediatric glaucoma trial using latanoprost.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01527682 | Phase 2 | Completed | 37 | Compared latanoprost vs dorzolamide for ocular hypotensive effect and safety in paediatric primary glaucoma refractory to surgery |
Literature Evidence
Currently no related literature available.
UK Market Information
This drug currently has no UK marketing authorisations on record in this Evidence Pack (market status: not marketed, 0 licences).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 2 RCT directly supports the ocular hypotensive effect of latanoprost in a closely related paediatric glaucoma population, and the mechanistic link to IOP-lowering in hereditary glaucoma is direct rather than speculative — but a single trial with modest enrolment (n=37) is not yet sufficient for unconditional proceeding.
To proceed, the following is needed:
- MHRA-approved product information/SmPC confirming original licensed indication, warnings and contraindications (currently a Blocking data gap)
- Confirmed mechanism of action data from DrugBank or SmPC
- Additional trials or real-world evidence specifically in adult and paediatric hereditary glaucoma populations
- UK marketing authorisation status confirmation, given current record shows the drug as not marketed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.